AlphaCrest Capital Management’s Coherus Oncology CHRS Stock Holding History

AlphaCrest Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-17,668	Closed	-$128K	–	1279
2022 Q2	$128K	Buy	+17,668	New	+$154K	0.01%	1228
2022 Q1	–	Sell	-80,239	Closed	-$1.28M	–	1265
2021 Q4	$1.28M	Buy	+80,239	New	+$1.4M	0.05%	674
2021 Q3	–	Sell	-76,800	Closed	-$1.06M	–	1256
2021 Q2	$1.06M	Buy	76,800 +33,260	+76%	+$471K	0.05%	638
2021 Q1	$636K	Sell	43,540 -4,816	-10%	-$81.8K	0.04%	689
2020 Q4	$840K	Sell	48,356 -10,218	-17%	-$182K	0.07%	384
2020 Q3	$1.07M	Buy	58,574 +36,412	+164%	+$677K	0.12%	236
2020 Q2	$396K	Sell	22,162 -9,659	-30%	-$163K	0.07%	490
2020 Q1	$516K	Buy	31,821 +16,373	+106%	+$303K	0.06%	556
2019 Q4	$278K	Buy	+15,448	New	+$285K	0.02%	1099

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

ACB

Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

AlphaCrest Capital Management's CHRS Position: Q3 2022 in Review

AlphaCrest Capital Management sold out of Coherus Oncology (CHRS) in Q3 2022, closing a stake of 17,668 shares — an estimated $128K sold.

AlphaCrest Capital Management first reported a position in CHRS in Q4 2019 and held it in 9 quarters. The position peaked at $1.28M in Q4 2021. 174 funds tracked by Wall St. Rank hold CHRS as of Q3 2022.

AlphaCrest Capital Management reported no remaining Coherus Oncology position as of Q3 2022 after selling out during the quarter.
AlphaCrest Capital Management sold 17,668 Coherus Oncology shares in Q3 2022, an estimated $128K.
AlphaCrest Capital Management first reported a position in Coherus Oncology in Q4 2019 and held it in 9 quarters.
AlphaCrest Capital Management's Coherus Oncology position peaked at $1.28M in Q4 2021.
174 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2022.

Based on AlphaCrest Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.